Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes

Journal of Investigative Medicine

Volumn 65, Issue 7, 2017, Pages 1057-1061

  Yoshimoto, Takuo ^a   Furuki, Takayuki ^b   Kobori, Hiroyuki ^a   Miyakawa, Masaaki ^c   Imachi, Hitomi ^a   Murao, Koji ^a   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Department of Medicine Hadanoeki ^*  (Japan)

^c Miyakawa Clinic   (Japan)

Author keywords

blood pressure; SGLT2 inhibitor; type 2 diabetes; urinary albumin; urinary angiotensinogen

Indexed keywords

ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN; ANGIOTENSINOGEN; BIGUANIDE; CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; ORAL ANTIDIABETIC AGENT; RENIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TOFOGLIFLOZIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CASE STUDY; CLINICAL ARTICLE; DESCRIPTIVE RESEARCH; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOCRINE FUNCTION; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION; UROGENITAL SYSTEM PARAMETERS; ALBUMINURIA; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIASTOLE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTOLE; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSINOGEN; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIASTOLE; FEMALE; HUMANS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SYSTOLE;

EID: 85030765903     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.1136/jim-2017-000445     Document Type: Article

References (34)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. Rathmann W, Giani G. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:2568-9.
3. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci 2005;109:143-59.
4. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-27.
5. Vallon V, Sharma K. Sodium-glucose transport: Role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens 2010;19:425-31.
6. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in Type 1 diabetes: Simultaneous glucose lowering and renal protection? Can J Diabetes 2014;38:356-63.
7. Turk E, Martín MG, Wright EM. Structure of the human na+/glucose cotransporter gene SGLT1. J Biol Chem 1994;269:15204-9.
8. Kanai Y, Lee WS, You G, et al. The human kidney low affinity na+/glucose cotransporter SGLT2. delineation of the Major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397-404.
9. Standards of medical care in diabetes-2016: Summary of revisions. Diabetes Care 2016;39(Suppl 1):S4-5.
10. Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453-67.
11. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 2016;59:1860-70.
12. Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin blockers. Diabetes Obes Metab 2016;18:590-7.
13. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-71.
14. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med 2015;373:2117-28.
15. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med 2016;375:323-34.
16. Haneda M, Seino Y, Inagaki N, et al. Influence of renal function on the 52-Week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in japanese patients with type 2 diabetes mellitus. Clin Ther 2016;38:66-88.
17. Cherney DZ, Perkins BA, Soleymanlou N, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 2014;86:1057-8.
18. Kobori H, Nangaku M, Navar LG, et al. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-87.
19. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci 2012;119:314-23.
20. Konishi Y, Nishiyama A, Morikawa T, et al. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy. Hypertension 2011;58:205-11.
21. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97.
22. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-93.
23. Inagaki N, Goda M, Yokota S, et al. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with Type 2 diabetes mellitus. Adv Ther 2015;32:1085-103.
24. Cherney DZ, Xiao F, Zimpelmann J, et al. Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. Can J Physiol Pharmacol 2014;92:703-6.
25. Saito T, Urushihara M, Kotani Y, et al. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci 2009;338:478-80.
26. Satou R, Kobori H, Katsurada A, et al. Quantification of intact plasma AGT consisting of oxidized and reduced conformations using a modified ELISA. Am J Physiol Renal Physiol 2016;311:F1211-6.
27. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33.
28. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-84.
29. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hosp Pract 2013;41:72-84.
30. Fonseca VA, Ferrannini E, Wilding JP, et al. Active-A nd placebo-controlled dosefinding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 2013;27:268-73.
31. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014;13:65.
32. Katsurada A, Hagiwara Y, Miyashita K, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007;293:F956-60.
33. Ohki T, Isogawa A, Toda N, et al. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line treatment for Non-Alcoholic Fatty liver disease patients with type 2 Diabetes Mellitus who do not respond to Incretin-Based therapies including Glucagon-like Peptide-1 analogs and Dipeptidyl Peptidase-4 inhibitors. Clin Drug Investig 2016;36:313-9.
34. Okamura Y, Ashida R, Yamamoto Y, et al. FIB-4 Index is a predictor of Background liver fibrosis and Long-Term Outcomes after curative resection of hepatocellular carcinoma. Ann Surg Oncol 2016;23(Suppl 4):467-74.